November 11, 2013
View Full PaperTargeting TNF-α for the treatment of inflammatory bowel disease
Key Points
Key points are not available for this paper at this time.
Abstract
TNF antagonists have become indispensable in the management of IBD. Efforts to focus on treatment of inflammatory signs only and on optimization of treatment with therapeutic drug monitoring are underway. The advent of several new compounds and "biosimilars" will further challenge the position of TNF antagonists in the treatment algorithm of IBD.
Cite This Study
Billiet et al. (Mon,) studied this question.